Location of Repository

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. : Activating STAT3 mutations in hepatocellular adenoma

By Camilla Pilati, Mohamed Amessou, Michel Bihl, Charles Balabaud, Jeanne Tran Van Nhieu, Valérie Paradis, Jean Charles Nault, Tina Izard, Paulette Bioulac-Sage, Gabrielle Couchy, Karine Poussin and Jessica Zucman-Rossi


International audienceInflammatory hepatocellular adenomas (IHCAs) are benign liver tumors. 60% of these tumors have IL-6 signal transducer (IL6ST; gp130) mutations that activate interleukin 6 (IL-6) signaling. Here, we report that 12% of IHCA subsets lacking IL6ST mutations harbor somatic signal transducer and activator of transcription 3 (STAT3) mutations (6/49). Most of these mutations are amino acid substitutions in the SH2 domain that directs STAT3 dimerization. In contrast to wild-type STAT3, IHCA STAT3 mutants constitutively activated the IL-6 signaling pathway independent of ligand in hepatocellular cells. Indeed, the IHCA STAT3 Y640 mutant homodimerized independent of IL-6 and was hypersensitive to IL-6 stimulation. This was associated with phosphorylation of tyrosine 705, a residue required for IL-6-induced STAT3 activation. Silencing or inhibiting the tyrosine kinases JAK1 or Src, which phosphorylate STAT3, impaired constitutive activity of IHCA STAT3 mutants in hepatocellular cells. Thus, we identified for the first time somatic STAT3 mutations in human tumors, revealing a new mechanism of recurrent STAT3 activation and underscoring the role of the IL-6-STAT3 pathway in benign hepatocellular tumorigenesis

Topics: STAT3, gp130, IL6ST, IL-6, beta-catenin, CTNNB1, HNF1A, IFN, SAA, CRP, SOCS3, JAK1, JAK2, Src, MESH : Adenoma, Liver Cell, MESH : Female, MESH : Humans, MESH : Interleukin-6, MESH : Liver Neoplasms, MESH : Male, MESH : Middle Aged, MESH : Models, Molecular, MESH : Mutant Proteins, MESH : Mutation, MESH : Phosphorylation, MESH : Adult, MESH : Protein Structure, Quaternary, MESH : RNA, Small Interfering, MESH : STAT3 Transcription Factor, MESH : Signal Transduction, MESH : Tyrosine, MESH : src-Family Kinases, MESH : Active Transport, Cell Nucleus, MESH : Aged, MESH : Base Sequence, MESH : Carcinoma, Hepatocellular, MESH : Cell Line, Tumor, MESH : Cytokine Receptor gp130, MESH : DNA, Neoplasm, MESH : Dimerization, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Publisher: Rockefeller University Press
Year: 2011
DOI identifier: 10.1084/jem.20110283
OAI identifier: oai:HAL:inserm-00719918v1
Provided by: Hal-Diderot

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.